Perioperative Statin Use May Reduce Postoperative Arrhythmia Rates After Total Joint Arthroplasty

Area of Science:

• Orthopedic Surgery
• Cardiology
• Pharmacology

Background:

• Postoperative arrhythmias increase morbidity and mortality in total joint arthroplasty (TJA) patients.
• Statins (HMG-CoA reductase inhibitors) are known to reduce atrial fibrillation after cardiac surgery.
• The cardioprotective effect of statins in TJA patients remains under investigation.

Purpose of the Study:

• To determine if perioperative statin administration decreases the incidence of 90-day postoperative arrhythmias in primary TJA patients.
• To evaluate the impact of simvastatin on cardiac arrhythmia development following hip and knee replacements.

Main Methods:

• A single-center retrospective cohort study matched 231 primary TJA patients receiving perioperative simvastatin (80 mg daily) with 966 controls.
• Documented new-onset arrhythmias and complications within 90 days post-procedure.
• Analyzed categorical variables using Fisher's exact tests.

Main Results:

• Arrhythmias occurred in 0.4% of patients receiving perioperative statins versus 4.0% in non-statin users (P = .003).
• A 10-fold reduction in relative risk for postoperative arrhythmias was observed.
• An absolute risk reduction of 3.6% was achieved with perioperative simvastatin.

Conclusions:

• Perioperative simvastatin significantly reduces the incidence of new-onset arrhythmias within 90 days of TJA.
• Treating 28 statin-naïve TJA patients with perioperative simvastatin can prevent one cardiac arrhythmia.
• Perioperative statin use demonstrates a cardioprotective benefit in TJA patients.